Short-chain fatty acid acetate triggers antiviral response mediated by RIG-I in cells from infants with respiratory syncytial virus bronchiolitis

Gut microbiota-derived short-chain fatty-acid (SFCA) acetate protects mice against RSV A2 strain infection by increasing interferon-β production and expression of interferon-stimulated genes (ISGs). However, the role of SFCA in RSV infection using strains isolated from patients is unknown. We first...

Full description

Saved in:

Bibliographic Details
Published in:	EBioMedicine Vol. 77; p. 103891
Main Authors:	Antunes, Krist H., Stein, Renato T., Franceschina, Caroline, da Silva, Emanuelle F., de Freitas, Deise N., Silveira, Josiane, Mocellin, Magáli, Leitão, Lidiane, Fachi, José L., Pral, Laís P., Gonzalez, Amanda, Oliveira, Sarah, Duarte, Leonardo, Cassão, Gisele, Gonçalves, João I.B., Reis, Tatiane M., Abbadi, Bruno L, Dornelles, Maiele, Sperotto, Nathália D.M., Rigo, Maurício, Rodrigues, Hosana, Jones, Marcus, Epifanio, Matias, Guima, Suzana, Setubal, João C., Jorge, Taissa R., Mansur, Daniel S., Mayer, Fabiana Q., Varela, Ana Paula M., Bizarro, Cristiano V., Machado, Pablo, Basso, Luiz A., Polack, Fernando P., Custovic, Adnan, Vinolo, Marco A.R., de Souza, Ana Paula D.
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier B.V 01-03-2022 Elsevier
Subjects:	Acetate Clinical isolates Respiratory syncytial virus RIG-I Clinical isolates RIG-I Respiratory syncytial virus Acetate
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Gut microbiota-derived short-chain fatty-acid (SFCA) acetate protects mice against RSV A2 strain infection by increasing interferon-β production and expression of interferon-stimulated genes (ISGs). However, the role of SFCA in RSV infection using strains isolated from patients is unknown. We first used RSV clinical strains isolated from infants hospitalized with RSV bronchiolitis to investigate the effects of in vitro SCFA-acetate treatment of human pulmonary epithelial cells. We next examined whether SCFA-acetate treatment is beneficial in a mouse model of RSV infection using clinical isolates. We sought to investigate the relationship of gut microbiota and fecal acetate with disease severity among infants hospitalized with RSV bronchiolitis, and whether treating their respiratory epithelial cells with SCFA-acetate ex-vivo impacts viral load and ISG expression. We further treated epithelial cells from SARS-CoV-2 infected patients with SCFA-acetate. In vitro pre-treatment of A549 cells with SCFA-acetate reduced RSV infection with clinical isolates and increased the expression of RIG-I and ISG15. Animals treated with SCFA-acetate intranasally recovered significantly faster, with reduction in the RSV clinical isolates viral load, and increased lung expression of IFNB1 and the RIG-I. Experiments in RIG-I knockout A549 cells demonstrated that the protection relies on RIG-I presence. Gut microbial profile was associated with bronchiolitis severity and with acetate in stool. Increased SCFA-acetate levels were associated with increasing oxygen saturation at admission, and shorter duration of fever. Ex-vivo treatment of patients’ respiratory cells with SCFA-acetate reduced RSV load and increased expression of ISGs OAS1 and ISG15, and virus recognition receptors MAVS and RIG-I, but not IFNB1. These SCFA-acetate effects were not found on cells from SARS-CoV-2 infected patients. SCFA-acetate reduces the severity of RSV infection and RSV viral load through modulation of RIG-I expression. FAPERGS (FAPERGS/MS/CNPq/SESRS no. 03/2017 - PPSUS 17/2551-0001380-8 and COVID-19 20/2551-0000258-6); CNPq 312504/2017-9; CAPES) - Finance Code 001.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 These authors contributed equally to this work.
ISSN:	2352-3964 2352-3964
DOI:	10.1016/j.ebiom.2022.103891